428 related articles for article (PubMed ID: 10083512)
1. Triple therapy with mycophenolate mofetil versus azathioprine.
Muñiz ML; Amenabar J; Gómez-Ullate P; Urbizu J; Lampreabe I
Transplant Proc; 1999; 31(1-2):1144-6. PubMed ID: 10083512
[No Abstract] [Full Text] [Related]
2. Safety and efficacy of mycophenolate mofetil for prophylaxis in Asian renal transplant recipients.
Suhail SM; Vathsala A; Lou HX; Woo KT
Transplant Proc; 2000 Nov; 32(7):1757-8. PubMed ID: 11119922
[No Abstract] [Full Text] [Related]
3. Mycophenolate mofetil as maintenance immunosuppression in pediatric renal transplantation.
Ettenger R; Cohen A; Nast C; Moulton L; Marik J; Gales B
Transplant Proc; 1997; 29(1-2):340-1. PubMed ID: 9123030
[No Abstract] [Full Text] [Related]
4. Postmarketing evaluation of mycophenolate mofetil-based triple therapy immunosuppression compared with a conventional azathioprine-based regimen reveals enhanced efficacy and early pharmacoeconomic benefit after renal transplantation.
Wüthrich RP; Weinreich T; Schwarzkopf AK; Candinas D; Binswanger U
Transplant Proc; 1998 Dec; 30(8):4096-7. PubMed ID: 9865310
[No Abstract] [Full Text] [Related]
5. Triple therapy with mycophenolate mofetil, cyclosporine, and prednisone in renal transplantation.
Crespo JF; Górriz JL; Sancho A; Avila A; Alcoy E; Pallardó LM
Transplant Proc; 1999 Sep; 31(6):2261-2. PubMed ID: 10500568
[No Abstract] [Full Text] [Related]
6. Single center analysis of mycophenolate mofetil and Neoral/prednisone therapy for prophylaxis of rejection in African-American and Caucasian transplant recipients.
Weber M; Ketchum RJ; Sellers M; Aradhye S; Deng S; Grossman R; Shaw L; Naji A; Barker C; Brayman KL
Transplant Proc; 1997; 29(1-2):338-9. PubMed ID: 9123029
[No Abstract] [Full Text] [Related]
7. Mycophenolate mofetil in ongoing chronic kidney allograft dysfunction.
Senn B; Rochat P; Schwarzkopf AK; Weinreich T; Binswanger U
Transplant Proc; 1998 Dec; 30(8):4075-6. PubMed ID: 9865301
[No Abstract] [Full Text] [Related]
8. Mycophenolate mofetil for the prevention of acute rejection of primary cadaveric kidney transplants: status of the MYC 1866 study at 1 year. The U.S. Mycophenolate Mofetil Study Group.
Transplant Proc; 1997; 29(1-2):348-9. PubMed ID: 9123033
[No Abstract] [Full Text] [Related]
9. Benefit of mycophenolate mofetil in patients with cyclosporine A-induced nephropathy after lung transplantation.
Zuckermann A; Birsan T; Thaghavi S; Kupilik N; Deviatko E; Dekan G; Wolner E; Klepetko W
Transplant Proc; 1999; 31(1-2):1160-1. PubMed ID: 10083518
[No Abstract] [Full Text] [Related]
10. Mycophenolate mofetil with lower cyclosporine dose in high-risk renal transplant recipients.
Esmeraldo RM; Donadi MO; Oliveira ML; Ponte CN; Pinheiro PM
Transplant Proc; 1999 Nov; 31(7):3007-8. PubMed ID: 10578367
[No Abstract] [Full Text] [Related]
11. Efficacy and safety of mycophenolate mofetil in different dosages in Asian renal allograft recipients.
Tsang WK; Tong KL; Yeung S; Lee W; Chan HW
Transplant Proc; 2000 Nov; 32(7):1755-6. PubMed ID: 11119921
[No Abstract] [Full Text] [Related]
12. Mycophenolate mofetil in renal transplantation: five years experience.
Tuncer M; Gürkan A; Erdoğan O; Demirbaş A; Süleymanlar G; Ersoy FF; Akaydin M; Yakupoğlu G
Transplant Proc; 2002 Sep; 34(6):2087-8. PubMed ID: 12270324
[No Abstract] [Full Text] [Related]
13. Omission of azathioprine and mycophenolate mofetil in immunosuppressive regimen in kidney transplantation.
Taheri M; Pourmand G; Mehrsai AR; Mansoori D
Transplant Proc; 2003 Nov; 35(7):2752-3. PubMed ID: 14612105
[No Abstract] [Full Text] [Related]
14. Improved outcome of steroid withdrawal in mycophenolate mofetil-treated primary cadaveric renal transplant recipients.
Kupin W; Venkat KK; Goggins M; Douzdjian V; Escobar F; Mozes M; Abouljoud M
Transplant Proc; 1999; 31(1-2):1131-2. PubMed ID: 10083505
[No Abstract] [Full Text] [Related]
15. Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report.
Jurewicz WA
Transplant Proc; 1999 Nov; 31(7A):64S-66S. PubMed ID: 10576048
[No Abstract] [Full Text] [Related]
16. Treatment of chronic rejection in renal transplantation by mycophenolate mofetil (MMF): a preliminary report of six-month experience.
Jirasiritham S; Sumethkul V; Mavichak V; Jirasiritham S; Chiewsilp P; Leenanupunth C; Kochakarn W
Transplant Proc; 1998 Nov; 30(7):3576-7. PubMed ID: 9838566
[No Abstract] [Full Text] [Related]
17. Management of massive proteinuria following renal transplantation with mycophenolate mofetil and blood pressure normalization.
Nakache R; Weinbroum A; Merhav H; Katz P; Kaplan E
Transplant Proc; 2001 May; 33(3):2294-5. PubMed ID: 11377533
[No Abstract] [Full Text] [Related]
18. A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients.
Fischer L; Sterneck M; Gahlemann CG; Malago M; Rogiers X; Broelsch CE
Transplant Proc; 2000 Nov; 32(7):2125-7. PubMed ID: 11120098
[No Abstract] [Full Text] [Related]
19. The early impact of mycophenolate mofetil in combination with steroids and cyclosporine Neoral after renal transplantation: a six-month analysis.
Cubas A; Herrero JC; Morales E; Carreño A; Dominguez-Gil B; Cirujeda A; Praga M; Ortuño T; Hernandez E; Delgado M; Andres A; Morales JM
Transplant Proc; 1999 Sep; 31(6):2265-6. PubMed ID: 10500570
[No Abstract] [Full Text] [Related]
20. Mycophenolate mofetil and reduction in cyclosporine dosage for chronic renal allograft dysfunction.
Islam MS; Francos GC; Dunn SR; Burke JF
Transplant Proc; 1998 Aug; 30(5):2230-1. PubMed ID: 9723452
[No Abstract] [Full Text] [Related]
[Next] [New Search]
